<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04905524</url>
  </required_header>
  <id_info>
    <org_study_id>V216</org_study_id>
    <nct_id>NCT04905524</nct_id>
  </id_info>
  <brief_title>Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)</brief_title>
  <official_title>Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viome</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Viome</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viome costumers are consented and recruited for this study and complete the questionnaires&#xD;
      upon enrollment. Any participant who previously self reported depression, anxiety, or&#xD;
      Irritable Bowel Syndrome (IBS) qualify for this study.&#xD;
&#xD;
      All participants receive Viome's diet, supplement and recommendations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants receive Viome Precision Nutrition Program (VPNP) after completing the health&#xD;
      assessment and questionnaire. VPNP consists of diet, supplement and recommendations based on&#xD;
      results from their sample results and their self reported questionnaire.&#xD;
&#xD;
      After approximately 5 months, participants were given the same health assessment&#xD;
      questionnaire.&#xD;
&#xD;
      The results and data collected before and after the VPNP are analyzed to find correlations&#xD;
      and differences between the measurements taken at the beginning of the trial and again&#xD;
      approximately 5 months after.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 19, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a single group cohort study; the first cohort consists of participants with self reported Irritable Bowel Syndrome (IBS), the second cohort consists of participants with self reported depression and the last cohort consists of participants with self reported anxiety.&#xD;
All cohorts receive diet and supplement recommendations from Viome based on participants' sample results.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease activity changes for IBS</measure>
    <time_frame>~5 months</time_frame>
    <description>Change of disease activity measurements in participants with self reported IBS after they have received Viome Precision Nutrition Program (VPNP), which consists of dietary supplement recommendations from Viome using clinically validated questionnaires. For IBS, Rome IV classification and criteria based on interpretation and self reporting of IBS, experience and symptoms were used to measure before and after VPNP for approximate duration of 5 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity changes depression</measure>
    <time_frame>~5 months</time_frame>
    <description>Change of disease activity measurements in participants with self reported depression after they have received Viome Precision Nutrition Program (VPNP), which consists of dietary supplement recommendations from Viome using clinically validated questionnaires. For depression, brief patient health questionnaire mood scale (PHQ-9) was used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity changes anxiety</measure>
    <time_frame>~5 months</time_frame>
    <description>Change of disease activity measurements in participants with self reported anxiety after they have received Viome Precision Nutrition Program (VPNP), which consists of dietary supplement recommendations from Viome using clinically validated questionnaires. For anxiety, General Anxiety Disorder 7 (GAD-7) was used, which is designed to assess the participants' health status during the previous 2 weeks.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Depression, Anxiety</condition>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Intervention arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All participants received the intervention in this trial (VPNP diet and supplement recommendations).</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>VIOME Precision Nutrition Program</intervention_name>
    <description>Diet and supplements recommendations</description>
    <arm_group_label>Intervention arm</arm_group_label>
    <other_name>VPNP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  PHQ-9 score 5 or above&#xD;
&#xD;
          -  GAD-7 score 5 or above&#xD;
&#xD;
          -  IBS ROME-IV score 125 or above&#xD;
&#xD;
          -  Females and males aged 18 years or older&#xD;
&#xD;
          -  Signed and dated informed consent prior to any trial-specific procedures are performed&#xD;
&#xD;
          -  Able to speak and read English&#xD;
&#xD;
          -  Willing and able to follow the trial instructions&#xD;
&#xD;
          -  Viome existing costumer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable/unwilling to complete the provided questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Momo Vuyisich, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Viome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronda Ramsey, MSHS</last_name>
    <phone>(425) 300-6933</phone>
    <email>studies@viome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mory Mehrtash, MSC</last_name>
    <phone>(425) 300-6933</phone>
    <email>studies@viome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Viome Research Institute</name>
      <address>
        <city>Bothell</city>
        <state>Washington</state>
        <zip>98011</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Momo Vuyisich, PhD</last_name>
      <phone>425-300-6933</phone>
      <email>studies@viome.com</email>
    </contact>
    <contact_backup>
      <last_name>Ronda Ramsey, MSHS</last_name>
      <email>studies@viome.com</email>
    </contact_backup>
    <investigator>
      <last_name>Momo Vuyisich, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2021</study_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Viome</investigator_affiliation>
    <investigator_full_name>Momchilo Vuyisich</investigator_full_name>
    <investigator_title>Study Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Anxiety</keyword>
  <keyword>Irritable bowel syndrome</keyword>
  <keyword>Viome precision nutrition program</keyword>
  <keyword>VNPN</keyword>
  <keyword>IBS</keyword>
  <keyword>PHQ9</keyword>
  <keyword>GAD7</keyword>
  <keyword>ROME-IV</keyword>
  <keyword>Viome</keyword>
  <keyword>Diet</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Supplements</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

